SA
Create Free Alerts
Azitra, Inc.AZTRNYSE
Loading
OverviewIntelligenceChartsNews

Latest News

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement
prnewswire.com

Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide").

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
prnewswire.com

Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

BRANFORD, Conn., March 5, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026.

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash
prnewswire.com

Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestones BRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484).

Azitra, Inc. to Present at BIO Investment & Growth Summit
prnewswire.com

Azitra, Inc. to Present at BIO Investment & Growth Summit

BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
prnewswire.com

Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

BRANFORD, Conn. , Dec. 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide.

Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why
defenseworld.net

Azitra (NYSEAMERICAN:AZTR) Trading Down 4.7% – Here’s Why

Shares of Azitra, Inc. (NYSEAMERICAN:AZTR - Get Free Report) traded down 4.7% on Thursday. The stock traded as low as $0.3593 and last traded at $0.3650. 275,800 shares were traded during trading, a decline of 20% from the average session volume of 343,099 shares. The stock had previously closed at $0.3830. Wall Street Analysts

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
prnewswire.com

Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules

BRANFORD, Conn. , Nov. 24, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,687,500 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,687,500 shares of common stock, in a private placement priced at a premium to market under NYSE rules (the "Offering").

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
prnewswire.com

Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

BRANFORD, Conn. , Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update.

Azitra, Inc. Addresses False Report Regarding Sale of Securities
prnewswire.com

Azitra, Inc. Addresses False Report Regarding Sale of Securities

BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering.

Azitra Receives Notice of Non-Compliance from NYSE American
prnewswire.com

Azitra Receives Notice of Non-Compliance from NYSE American

BRANFORD, Conn. , Oct. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide.

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
prnewswire.com

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended June 30, 2025, and provided a business update.

Azitra, Inc. Announces Reverse Stock Split
prnewswire.com

Azitra, Inc. Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 6.66 pre-split shares.

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
prnewswire.com

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International Convention BRANFORD, Conn. , June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance